PT-141 (Bremelanotide) · Research brief

PT-141 Bioavailability — What Affects Absorption Rates

Q: What is the bioavailability of PT-141 when administered subcutaneously?

Subcutaneous PT-141 achieves greater than 95% bioavailability because the peptide enters systemic circulation directly through capillary beds in the hypodermis without encountering hepatic first-pass metabolism or mucosal enzymatic degradation. This route bypasses the barriers that limit absorption via other administration methods, delivering nearly the entire dose to melanocortin-4 receptors in active form. Peak plasma concentration occurs 30–60 minutes post-injection with a half-life of approximately 2.7 hours.

Q: Why is nasal spray PT-141 bioavailability so much lower than injection?

Intranasal PT-141 bioavailability is limited to approximately 2.6% due to aminopeptidases and carboxypeptidases in the nasal mucosa that degrade the peptide before it can cross the epithelial barrier into submucosal capillaries. The peptide’s molecular weight (1025.2 Da) and hydrophilic structure prevent passive diffusion across lipid membranes, so absorption depends on inefficient paracellular transport through tight junctions. Clinical data show that 20 mg administered intranasally produces lower systemic exposure than 1.75 mg injected subcutaneously.

Q: Can oral PT-141 be absorbed at all, or is it completely ineffective?

Oral PT-141 results in negligible bioavailability (less than 0.5%) because gastric acid denatures the peptide structure and pepsin hydrolyses peptide bonds in the stomach, while any fragments that survive encounter trypsin and chymotrypsin in the small intestine. The intestinal epithelial barrier prevents absorption of molecules larger than 600 Da, and PT-141 at 1025.2 Da cannot cross passively or via active peptide transporters designed for smaller molecules. Hepatic first-pass metabolism further degrades any trace amounts that might be absorbed.

Q: How does improper storage affect PT-141 bioavailability?

Temperature excursions above 8°C cause time-dependent peptide degradation — reconstituted PT-141 stored at room temperature loses 10–15% potency within 48 hours due to oxidation and hydrolysis, and functional bioavailability drops below 70% after one week at ambient temperature. Aggregation caused by freezing, vigorous shaking, or prolonged heat exposure reduces the fraction of peptide in bioactive monomeric form even if the solution remains clear. Proper storage at 2–8°C maintains structural integrity and ensures that subcutaneous injection delivers the expected systemic exposure.

Q: What is the difference between absolute bioavailability and functional bioavailability for PT-141?

Absolute bioavailability refers to the percentage of administered dose that reaches systemic circulation intact, while functional bioavailability describes the fraction that reaches target melanocortin-4 receptors in active form capable of producing a physiological response. Subcutaneous PT-141 achieves both metrics at greater than 95%, but improperly stored peptide may reach circulation at high absolute bioavailability while functional bioavailability is reduced due to structural degradation or aggregation. This distinction matters for research protocols where receptor occupancy, not just plasma concentration, determines outcomes.

Q: Why was intranasal PT-141 abandoned in clinical trials despite being non-invasive?

Intranasal bremelanotide was abandoned after Phase 2 trials because absorption variability exceeded 40% between subjects and absolute bioavailability remained below 3%, making reliable dose titration impossible. The low and inconsistent systemic exposure meant researchers couldn’t establish predictable dose-response relationships, which is essential for regulatory approval and therapeutic application. Subcutaneous injection produces reproducible pharmacokinetic curves with minimal inter-subject variability, allowing precise dosing — the trade-off of invasiveness for consistency was deemed necessary for clinical viability.

Q: Can absorption enhancers or encapsulation improve oral PT-141 bioavailability?

No published data supports meaningful oral bioavailability improvement for PT-141 using absorption enhancers, enteric coatings, or liposomal encapsulation. While these strategies work for some smaller peptides, PT-141’s molecular weight and susceptibility to gastric and intestinal proteases create a degradation rate that exceeds what formulation technology can overcome. Enteric coatings protect against gastric acid but not intestinal enzymes, and absorption enhancers increase epithelial permeability but cannot reverse peptide hydrolysis. Any commercial product claiming effective oral delivery lacks pharmacokinetic validation.

Q: How much intranasal PT-141 is required to match 1.75 mg subcutaneous injection?

Based on clinical pharmacokinetic data, approximately 30–40 mg of intranasal PT-141 is required to produce systemic exposure comparable to 1.75 mg administered subcutaneously — a 17–23 fold increase in dose. Even at these higher nasal doses, absorption remains inconsistent, with coefficient of variation exceeding 40% between administrations. This dose conversion is impractical for most research applications because it increases cost, requires multiple spray actuations per dose, and introduces uncontrolled variability that makes reproducible receptor-binding studies nearly impossible.

Q: Does reconstituting PT-141 with sterile water instead of bacteriostatic water affect bioavailability?

Reconstituting with sterile water instead of bacteriostatic water does not immediately affect PT-141 bioavailability if the peptide is used within 24–48 hours, but bacterial contamination risk increases significantly without the benzyl alcohol preservative present in bacteriostatic water. Contaminated solutions can trigger immune responses or introduce endotoxins that interfere with research outcomes, even if the peptide itself remains structurally intact. For multi-dose vials stored beyond 48 hours, bacteriostatic water is essential — sterile water without preservative allows microbial growth that degrades peptide purity and introduces uncontrolled variables.

Q: What happens to PT-141 bioavailability if the peptide is injected intramuscularly instead of subcutaneously?

Intramuscular injection of PT-141 produces systemic absorption comparable to subcutaneous administration (both exceed 90% bioavailability) because the peptide still bypasses hepatic first-pass metabolism and mucosal enzymatic barriers. The primary difference is absorption kinetics: intramuscular injection may produce a slightly faster time to peak plasma concentration due to higher blood flow in skeletal muscle compared to subcutaneous adipose tissue. However, subcutaneous injection remains the standard route because it causes less tissue trauma, allows easier self-administration in research subjects, and produces more predictable pharmacokinetic curves across varying injection sites.

Real Peptides Research TeamEditorial

Updated June 5, 202610 min read

44 WORDS

Short answer

Key takeaways

PT-141 bioavailability via subcutaneous injection exceeds 95%, delivering nearly the entire dose to systemic circulation without hepatic first-pass metabolism.
Intranasal PT-141 absorption is limited to approximately 2.6% due to mucosal peptidases and epithelial barrier constraints, requiring 10–20 times the subcutaneous dose for equivalent plasma exposure.
Oral administration of PT-141 results in negligible bioavailability (<0.5%) because gastric acid and intestinal proteases degrade the peptide before absorption.
The peptide's molecular weight (1025.2 Da) and hydrophilic structure prevent passive membrane diffusion, making delivery route the single most critical variable in determining therapeutic efficacy.
Commercial nasal spray formulations claiming 'comparable efficacy' to injectable PT-141 at similar doses misrepresent absorption pharmacokinetics. Systemic exposure from nasal delivery is a fraction of subcutaneous injection at identical concentrations.

A 2007 pharmacokinetic study published in the Journal of Clinical Pharmacology found that PT-141 (bremelanotide) administered subcutaneously achieved systemic absorption rates exceeding 95%, while intranasal delivery barely crossed 2.6%. A 36-fold difference in the amount of active peptide reaching melanocortin-4 receptors in the hypothalamus. That gap isn't a minor variance; it's the difference between a therapeutic dose and a subtherapeutic one, regardless of how much peptide you start with.

We've worked with researchers navigating peptide sourcing for years. The single most misunderstood variable in PT-141 protocols isn't purity or reconstitution technique. It's delivery route. Most suppliers discuss peptide concentration but never address what percentage of that concentration survives first-pass metabolism, enzymatic degradation in mucosal tissue, or simply poor membrane permeability. PT-141 bioavailability is the gatekeeper between purchasing a compound and achieving the physiological response that compound is capable of producing.

What determines PT-141 bioavailability in research settings?

PT-141 bioavailability is determined primarily by administration route: subcutaneous injection bypasses hepatic first-pass metabolism entirely, achieving near-complete systemic absorption (>95%), while intranasal delivery faces mucosal barriers and proteolytic enzymes that degrade the peptide before it enters circulation, limiting absorption to approximately 2.6%. Oral administration results in negligible bioavailability (<1%) due to gastric acid hydrolysis and intestinal peptidase activity. The peptide's hydrophilic structure and molecular weight (1025.2 Da) prevent passive diffusion across lipid membranes, making delivery method the single most critical variable in determining how much active bremelanotide reaches target melanocortin receptors.

Here's what most peptide guides miss: PT-141 bioavailability isn't a fixed percentage. It's a spectrum shaped by enzymatic activity, membrane transport efficiency, and metabolic clearance rates that vary not just by route but by formulation stability and reconstitution technique. A subcutaneous injection of improperly stored PT-141 doesn't deliver the same systemic exposure as a fresh preparation at identical concentration. This article covers the pharmacokinetic mechanisms that determine absorption, the quantitative differences between delivery routes, what actually happens to the peptide molecule between administration and receptor binding, and why most commercial nasal spray formulations fundamentally misrepresent their effective dose.

Why Subcutaneous Injection Achieves Maximum PT-141 Bioavailability

Subcutaneous injection delivers PT-141 directly into the hypodermis. The layer of adipose and connective tissue beneath the dermis where capillary beds are dense enough to support rapid systemic absorption but enzymatic activity is minimal compared to mucosal surfaces or the gastrointestinal tract. Once reconstituted bremelanotide is injected into this tissue, the peptide diffuses into adjacent capillaries through fenestrations in the endothelial wall, entering venous circulation without encountering hepatic metabolism first. This is the definition of 100% bioavailability: the entire administered dose reaches systemic circulation in its active form.

The peptide's structure. A cyclic heptapeptide with a molecular weight of 1025.2 Da. Is too large for passive diffusion across lipid membranes but small enough to pass through capillary fenestrations (typically 5–10 nm in diameter). Subcutaneous tissue contains minimal peptidase activity compared to mucosal epithelium, so enzymatic degradation before absorption is negligible. Peak plasma concentration (Cmax) occurs approximately 30–60 minutes post-injection, with a half-life of 2.7 hours. Short enough to clear within 12–18 hours but long enough to maintain therapeutic receptor occupancy during the exposure window.

Our team has worked with labs running receptor-binding assays on PT-141, and the consistency of subcutaneous delivery is what makes dose-response curves reproducible. When you inject 1.75 mg subcutaneously, you can expect approximately 1.66–1.70 mg to reach melanocortin-4 receptors in the hypothalamus within the first hour. That predictability is what allows researchers to titrate doses with confidence. Nasal sprays, by contrast, produce erratic plasma curves because mucosal absorption depends on variables no one can standardise. Sinus congestion, mucus viscosity, spray technique, and individual variations in nasal epithelial permeability.

The Enzymatic Barrier: Why Nasal PT-141 Bioavailability Stays Below 3%

Intranasal PT-141 administration was the original delivery method explored in early clinical trials, but it was abandoned for subcutaneous injection after Phase 2 data revealed two insurmountable problems: absorption variability (CVs exceeding 40% between subjects) and absolute bioavailability capped at 2.6%. The nasal mucosa is rich in aminopeptidases and carboxypeptidases. Enzymes that cleave peptide bonds at terminal amino acids. Which begin degrading bremelanotide the moment it contacts the epithelial surface. Before the peptide can cross the mucosal barrier into submucosal capillaries, a significant fraction is already hydrolysed into inactive fragments.

The mucosal epithelium itself presents a physical barrier: the peptide must cross a layer of columnar epithelial cells connected by tight junctions, then traverse the basement membrane and enter fenestrated capillaries in the lamina propria. PT-141's hydrophilic structure prevents it from crossing lipid bilayers passively, so absorption depends on paracellular transport (squeezing between cells through tight junction gaps) or transcytosis (vesicular transport across the cell). Both pathways are inefficient for molecules above 500 Da, and PT-141 exceeds that threshold by more than double.

Clinical pharmacokinetic data from Palatin Technologies' Phase 2 trials showed that intranasal bremelanotide at 20 mg produced a mean Cmax of 2.1 ng/mL, while subcutaneous injection of 1.75 mg produced a Cmax of 8.4 ng/mL. Despite the nasal dose being 11 times larger. The math is blunt: you need roughly 40 mg intranasally to match the systemic exposure of 1.75 mg subcutaneously. Most commercial nasal sprays contain 10–15 mg per dose and claim 'comparable efficacy' to injectable forms without disclosing this absorption deficit.

Oral PT-141 Bioavailability: Why It Doesn't Work

Oral peptide delivery fails for PT-141 because the gastrointestinal tract is an enzymatic gauntlet designed to break down dietary proteins into absorbable amino acids. Gastric acid (pH 1.5–3.5) denatures peptide secondary structure within minutes, and pepsin. The stomach's primary protease. Cleaves peptide bonds indiscriminately. Even if a fraction of PT-141 survived the stomach intact, it would encounter trypsin, chymotrypsin, and elastase in the small intestine, all of which hydrolyse peptide bonds at specific amino acid residues.

The few peptide molecules that escape enzymatic degradation still face the intestinal epithelial barrier. A single layer of enterocytes connected by tight junctions that prevent paracellular transport of molecules larger than 600 Da. PT-141 cannot cross this barrier passively. Active transport mechanisms (peptide transporters like PEPT1) exist for dipeptides and tripeptides but not for cyclic heptapeptides. Hepatic first-pass metabolism compounds the problem: any peptide absorbed from the intestine enters the hepatic portal vein and passes through the liver before reaching systemic circulation, where hepatic peptidases degrade what little remains.

Published bioavailability data for oral bremelanotide is effectively zero. Studies report <0.5% systemic absorption, and even that figure likely reflects assay noise rather than intact peptide. Encapsulation strategies (enteric coating, liposomal delivery) have been explored for other peptides but remain unproven for PT-141. Our experience reviewing peptide formulations shows that 'oral PT-141' products are either mislabelled or deliberately misleading. The compound reaching circulation after oral administration is negligible, and no amount of 'absorption enhancers' can overcome the combined enzymatic and barrier challenges of the GI tract.

PT-141 Bioavailability: Route Comparison

Administration Route	Absolute Bioavailability	Time to Peak Plasma (Tmax)	Typical Dose Required	Enzymatic Degradation	Bottom Line: Research Viability
Subcutaneous Injection	>95%	30–60 minutes	1.75–2.0 mg	Minimal (capillary absorption bypasses mucosal enzymes)	Gold standard. Predictable dose-response, reproducible plasma curves, suitable for all research protocols requiring precise receptor occupancy
Intranasal Spray	2.6%	45–90 minutes	20–40 mg	High (aminopeptidases and carboxypeptidases in nasal mucosa)	Inconsistent. Absorption varies 40%+ between administrations, requires 10–20× dose to match subcutaneous exposure, not suitable for quantitative receptor studies
Oral (tablet/capsule)	<0.5%	N/A (negligible absorption)	Not viable	Extreme (gastric acid + pepsin + intestinal proteases)	Non-viable. Systemic exposure insufficient for melanocortin receptor activation, no published data supporting efficacy at any oral dose
Sublingual (off-label)	~5–8% (estimated)	20–40 minutes	10–15 mg	Moderate (salivary amylase + oral mucosa peptidases)	Theoretical only. No published pharmacokinetic data for PT-141, likely better than oral but far worse than subcutaneous, absorption highly variable

What If: PT-141 Bioavailability Scenarios

What If I Reconstitute PT-141 Incorrectly — Does It Affect Bioavailability?

Use bacteriostatic water at the specified ratio and inject it slowly down the vial wall to avoid shearing forces that denature the peptide structure. If you reconstitute with sterile water instead of bacteriostatic water, bacterial contamination risk increases but bioavailability remains unchanged as long as the peptide itself isn't degraded. Vigorous shaking or exposure to temperatures above 25°C during reconstitution can cause aggregation. Visible as cloudiness or particulates. Which reduces the fraction of peptide in bioactive monomeric form. Aggregated peptide may still dissolve but won't bind melanocortin receptors effectively, lowering functional bioavailability even if subcutaneous injection technique is correct.

What If I Store Reconstituted PT-141 at Room Temperature — How Fast Does Bioavailability Decline?

Refrigerate reconstituted PT-141 at 2–8°C immediately after mixing and use within 28 days for maximum stability. At room temperature (20–25°C), peptide degradation accelerates. Studies on similar cyclic peptides show 10–15% potency loss within 48 hours at ambient temperature due to oxidation and hydrolysis. After one week at room temperature, expect functional bioavailability to drop below 70% of the original dose even if subcutaneous injection is performed correctly. The peptide doesn't 'go bad' visually. Degradation products remain colourless and soluble. So appearance isn't a reliable stability indicator. Temperature excursions during shipping are the most common cause of reduced bioavailability in peptides sourced from non-specialised suppliers.

What If I Use a Nasal Spray Formulation — Can I Compensate with Higher Doses?

You can increase the nasal dose to partially compensate for low bioavailability, but absorption remains unpredictable and dose-response curves flatten above 30 mg due to mucosal saturation. Even at 40 mg intranasally, you may only achieve systemic exposure equivalent to 1.0–1.2 mg subcutaneously. And that exposure will vary by 40% or more between administrations depending on sinus congestion, spray technique, and mucosal blood flow. Intranasal delivery was explored in clinical trials precisely because it's non-invasive, but it was abandoned after Phase 2 due to inconsistent pharmacokinetics that made dose titration unreliable. For research applications requiring reproducible receptor occupancy, subcutaneous injection is the only route with sufficient bioavailability consistency.

The Unvarnished Truth About PT-141 Delivery Routes

Here's the honest answer: if you're using PT-141 in a research protocol where dose precision matters. Receptor-binding assays, dose-response studies, metabolic signalling experiments. Anything other than subcutaneous injection is introducing uncontrolled variability that will make your data uninterpretable. Nasal sprays sound convenient, and suppliers market them as 'user-friendly alternatives,' but the absorption pharmacokinetics are so erratic that you can't reliably correlate dose with outcome. You're not getting 2.6% of your dose every time. You're getting somewhere between 1% and 4%, and you won't know which until plasma levels are measured.

Oral formulations are worse: they're biochemically implausible. The peptide doesn't survive the stomach. Marketing claims about 'enteric coatings' or 'absorption enhancers' are either aspirational (hoping future technology solves the problem) or deliberately misleading. We've seen labs waste months trying to optimise oral dosing schedules before accepting that the bioavailability deficit isn't something you can overcome with timing or co-administration strategies. The peptide is being destroyed before it ever reaches circulation.

Sublingual administration occupies a middle ground. Theoretically better than oral, worse than subcutaneous. But there's no published pharmacokinetic data for PT-141 via this route, so anyone using it is operating without a validated dose conversion. If subcutaneous injection isn't viable for your application, accept that you're trading precision for convenience and design your protocols accordingly. Don't assume equivalent efficacy across routes and then wonder why results don't replicate.

PT-141 bioavailability isn't a fixed peptide characteristic. It's a function of how you deliver it. Subcutaneous injection achieves near-total systemic absorption because it bypasses the enzymatic and barrier challenges that degrade peptides in mucosal and gastrointestinal environments. Intranasal delivery limits absorption to 2.6% due to mucosal peptidases and tight epithelial junctions, while oral administration results in negligible bioavailability because gastric acid and intestinal proteases hydrolyse the peptide before it can be absorbed. The peptide's molecular weight and hydrophilic structure mean it cannot passively cross lipid membranes, making delivery route the dominant variable in determining whether administered PT-141 reaches melanocortin-4 receptors in sufficient concentration to produce a physiological response. For research applications requiring reproducible dose-response relationships, subcutaneous injection remains the only route with pharmacokinetic consistency.

At Real Peptides, we supply PT-141 synthesised with exact amino-acid sequencing and verified purity. But the compound's research utility depends entirely on how it's administered. If your protocol demands precise receptor occupancy or quantifiable plasma exposure, route selection isn't optional. Subcutaneous delivery is the baseline for reproducible data.

References

Peer-reviewed sources on PT-141 (Bremelanotide) indexed in PubMed, listed for research context. Real Peptides supplies PT-141 (Bremelanotide) for laboratory research use only.

Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. Journal of sex research, 2024. PMID 36809187. doi:10.1080/00224499.2023.2175192
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert opinion on pharmacotherapy, 2023. PMID 36242769. doi:10.1080/14656566.2022.2132144
Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurology international, 2022. PMID 35076581. doi:10.3390/neurolint14010006
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS spectrums, 2022. PMID 33455598. doi:10.1017/S109285292100002X
Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of women's health (2002), 2022. PMID 35147466. doi:10.1089/jwh.2021.0191
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of women's health (2002), 2022. PMID 35230162. doi:10.1089/jwh.2021.0225
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. Journal of sex research, 2021. PMID 33678061. doi:10.1080/00224499.2021.1885601
Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. Drug and therapeutics bulletin, 2021. PMID 34642243. doi:10.1136/dtb.2021.000020

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions